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CD4+ TH1 HELPER CELLS: THE UNIFYING LINK BETWEEN 
PERIODONTITIS AND TYPE II DIABETES MELLITUS INFLAMMATION 
 
CHLOE HABIB 
ABSTRACT 
 Periodontitis (PD) and type II diabetes mellitus (T2D) are chronic inflammatory 
diseases that affect populations worldwide. While it has been well established clinically 
that T2D is a risk factor for PD, previous studies have failed to determine the molecular 
mechanism linking T2D and PD. As a result, the objectives of this study were as follows: 
to characterize the inflammation present in gingival tissue immune cells in subjects with 
periodontitis (PD) and subjects with type II diabetes mellitus and periodontitis (T2D/PD) 
compared with healthy subjects (H); to identify the effect of T2D on inflammation in PD; 
and to determine the predominant cell type responsible for the production of pro-
inflammatory cytokines. Using flow cytometry to sort and purify cells based on CD45+ 
cell surface expression into CD4+, CD8+, CD11b+, CD19+, and CD56+ cell subgroups, we 
used the Enzyme Linked ImmunoSpot (ELISPOT) assay to quantify cytokine production 
in gingival cells from the three groups (H, PD, and T2D/PD). We identified CD4+ T 
helper cells as the predominant cell type in gingival tissues from T2D/PD subjects and 
found that these cells produced higher concentrations of Th1 cytokines IL-2, IL-10, IFN-
γ, and TNF-α in T2D/PD subjects than in H and PD subjects. As a result, we concluded 
that T2D increases inflammation in PD by an increase Th1 cell persistence.  
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INTRODUCTION 
 
Unresolved inflammation in PD and T2D 
Periodontal disease is a chronic inflammatory disease that affects the tooth-
supporting periodontal bone and surrounding gingival tissue. One out of every two 
American adults (47.2%) over the age of 30 are affected by this disease (NHANES 2009-
2010). The condition is also globally common, with 11.2% of world’s population 
diagnosed with periodontal disease (Kassebaum et al., 2014). Periodontal disease can 
have a significant impact on quality of life and is one of the main causes of edentulism 
(tooth loss) due to alveolar bone destruction. Numerous research efforts have been 
initiated to understand the underlying causes of periodontal disease, which will target the 
development of more effective preventative and treatment strategies. 
Type II diabetes mellitus (T2D) is a major risk factor for the development of 
periodontal disease (Salvi et al., 2008; Chavarry et al., 2009; Khader et al., 2006). 
Individuals with T2D are 2.8 times more likely to have clinical attachment loss and 3.4 
times more likely to have radiographic bone loss than normoglycemic individuals 
(Emrich et al., 1991; Shlossman et al., 1990). Furthermore, periodontal disease can 
worsen the severity of T2D by affecting glycemic control according to at least some 
reports (Khader et al., 2006; Grossi and Genco, 1998; Hugoson et al., 1989; Thorstensson 
and Hugoson, 1993). While there is a lack of consensus in the literature on the molecular 
mechanism linking T2D and periodontal disease, it is agreed that the chronic 
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inflammatory states of both conditions provide the connection for this two-way 
relationship between T2D and periodontal disease (Grossi and Genco, 1998).  
 The earliest stage of periodontal disease is gingivitis: reversible and localized 
inflammation of the gingiva caused by bacteria in the dental plaque that forms a 
microbial biofilm on the teeth and gingiva. Without intervention, gingivitis may progress 
to periodontitis (PD): chronic inflammation that results in loss of gingiva, tooth 
supporting ligaments, and alveolar bone. Without intervention, such as a deep cleaning 
procedure called scaling and root planing (SRP), PD may result in edentulism. In 
addition, periodontal pockets (abnormal depth) form between the tooth and connective 
tissues due to loss of gingival attachment caused by ligament degradation. Probing depth 
of the periodontal pocket and radiographs that determine the severity of alveolar bone 
resorption are measured clinically to characterize the severity of PD.  
 While certain bacterial species, such as P. gingivalis, A. actinomycetemcomitas, 
and T. forsythia have been identified as periodontal pathogens, there has been no 
consensus in the literature as to the specific species of virulent bacteria that dominates in 
PD (Perez-Chaparro, 2014; Perez-Chaparro, 2016; Silva et al., 2015). Rather, it is 
hypothesized that a dysbiosis of the microbial biofilm is responsible for disease 
pathogenesis (Feres et al., 2016). Bacterial components, such as lipopolysaccharides 
(LPS), peptidoglycans, lipoteichoic acids, proteases and toxins from the microbial 
challenge initiate a local inflammatory response in the host periodontium (tooth 
supporting structures) (Yucel-Lindberg and Bage, 2013). This innate host response is 
initiated by toll-like receptors (TLRs) on the surface of resident cells of the periodontal 
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tissue: epithelial cells, gingival and periodontal ligament fibroblasts, osteoblasts, and 
dendritic cells) (Hans and Hans, 2011; Di Benedetto et al., 2013). TLRs recognize a large 
number of pathogen-associated molecular patterns and activate innate immune pathways 
that lead to pro-inflammatory cytokine production, such as IL-1, IL-6, PGE2, and TNF-α 
(Trevani et al., 2003; Baker, 2000; Preshaw and Taylor, 2011). Yoshioka et al. (2008) 
found that LPS from gram-negative periodontal bacteria stimulates the production of pro-
inflammatory cytokines via TLR2 and TLR4, indicating that periodontal bacteria can 
cause an immunological host response via the TLR receptors. In turn, pro-inflammatory 
cytokines promote osteoclastogenesis, leading to alveolar bone resorption. After the 
initial innate host response of approximately 21 days, the adaptive host response 
dominates and is mediated by T cells, B cells, and other antigen-presenting cell types (Di 
Benedetto et al., 2013). B and T cells contribute to osteoclast activation and thus 
periodontal bone loss by producing pro-inflammatory cytokines such as RANKL, IL-17, 
and TNF-α (Hienz et al., 2015).  
 It is perhaps unsurprising that the types of pro-inflammatory cytokines overlap in 
T2D and PD (Chang and Lim, 2012; Naguib et al., 2004) given that both diseases are 
characterized by unresolved inflammation (Lacopino, 2001). T2D is characterized by 
glucose intolerance, insulin resistance, and, like PD, low grade chronic inflammation 
(Zhu and Nikolajczyk, 2014). T2D-associated inflammation is driven at least in part by 
hyperglycemia, which can cause irreversible and non-enzymatic glycation of proteins and 
lipids leading to the formation of advanced glycation end-products (AGEs) (Taylor et al., 
2013). AGEs, which engage the receptor for advanced glycation end-products (RAGEs), 
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broadly activate inflammation and may predispose to PD in people who have T2D (Amir 
et al., 2011; Zhu and Nikolajczyk, 2014). 
 Additionally, obesity is a risk factor for T2D and contributes to the chronic 
inflammatory state of PD (Esser et al., 2014). The obese state is characterized by 
expanded adipose tissue depots. In response to certain conditions, such as high fat intake, 
adipocytes secrete adipokines (adipose hormones), such as pro-inflammatory leptin and 
anti-inflammatory adiponectin. As a result, the anti-inflammatory milieu characteristic of 
the lean state transitions to a pro-inflammatory state due to the expansion of adipose 
tissue and a resulting increase in leptin and cytokine/chemokine secretion, including IL-6, 
along with a decrease in adiponectin secretion (Dandona et al., 2004; Zhu and 
Nikolajczyk, 2014). An examination of NHANES III data found a positive association 
between body mass index (BMI), a measure of obesity, and clinical attachment loss in 
participants without diabetes. Those in the highest quartile of BMI had significantly 
higher serum concentrations of TNF-α and TNF-α receptor than those in the lowest 
quartile, indicating that obesity is associated with systemic inflammation and PD (Genco 
et al., 2005). Furthermore, higher amounts of IL-6 and TNF-α are present in gingival 
crevicular fluid (GCF) (fluid from the space between the tooth and gingival tissues) in 
obesity, T2D, and PD (Duarte et al., 2014; Dandona et al., 2004; Sonnenschein and 
Meyle, 2000) and further emphasize overlap in inflammatory mediators amongst these 
diseases. While the two-way relationship between T2D and PD, aggravated by obesity, 
likely creates a vicious cycle that exacerbates both diseases, the immunopathogenesis of 
the two diseases remains incompletely defined in people (Kumar et al., 2014; Zhu et al., 
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2014), despite demonstrations that unresolved B and T cell-mediated inflammation is the 
underlying connection between T2D and PD in mouse models (Zhu et al., 2014).  
 
The role of B cells in PD and T2D 
 B cells play a role in both PD and T2D and may be responsible for the unresolved 
inflammation linking the two diseases. B cells act as antigen presenting cells (APCs) by 
internalizing antigens through surface immunoglobulins. The antigen is then degraded as 
peptides and non-covalently binds to class II molecules of the major histocompatibility 
complex (MHC), which is transported to the B cell surface for presentation to CD4+ T 
helper cells  (Berglundh et al., 2007; O’Shea and Paul, 2008). Gemmell et al. (2002) 
found that B cells were the predominant type of APCs (over other APCs like 
macrophages and dendritic cells) in PD lesions taken from human gingival biopsies and 
suggested that B cell antigen presentation may allow further activation and clonal 
expansion of T cells. Other groups concurred that B cells and plasma cells, the terminally 
differentiated relative of B cells, are the dominant cell types in PD lesions, making up 
>65% of the cell population (Berglundh et al., 2007; Nikolajczyk, 2010). B cell 
dominance follows an initial infiltration by neutrophils and monocytes (Seymour et al., 
1979). Furthermore, the proportion of B cells in the lesion corresponds to disease severity 
(Okada et al., 1983; Berglundh and Donati, 2005; Takahashi et al., 1996), suggesting that 
B cells promote rather than initiate PD (Nikolajczyk, 2010). It is unclear, however, 
whether B cells provide a protective or pathogenic role in PD. In chronic PD, B cells 
could facilitate bacterial clearance and contribute to halting disease progression mediated 
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through antibody production specific for PD pathogens (Zouali, 2017). Meghji et al. 
(1993) found that serum from patients with severe PD containing high titers of anti-P. 
gingivalis antibodies inhibited bone resorption compared with serum from patients with 
low anti-P. gingivalis titers. In a cohort of elderly individuals, however, the level of 
antibodies to periodontal bacteria positively correlated to bone loss (Wheeler et al., 
1994). Despite many additional studies, the role of antibodies, a B cell-specific product, 
remains unclear. 
 More recent work has shown that B cells are also a major source of many pro- and 
anti-inflammatory cytokines in PD, such as IL-10, IL-6, IL-8, IL-1β, and TNF-α 
(Jagannathan et al., 2009; Graves and Cochran, 2003). Given the abundance of B cells in 
PD lesions, it is likely that B cells hyper-produce cytokines via TLR receptor activation 
and are the major source of local and, perhaps, systemic inflammation in PD 
(Nikolajczyk, 2010). B cells are also major producers of RANKL, a cytokine that 
promotes osteoclastogenesis (Yasuda et al., 1998). In healthy gingiva, less than 20% of 
both B and T cells express RANKL. However, 50-60% of T cells and more than 90% of 
B cells from PD lesions express RANKL (Kawai et al., 2006). It is unclear whether this 
difference in proportion of RANKL+ cells indicates that B cells contribute more heavily 
to alveolar bone resorption than T cells in PD lesions. Regardless, additional studies 
concur that B and T cells are the primary sources of RANKL in PD (Kawai et al., 2006). 
B cells may also contribute to osteoclastogenesis by up regulating IL-6, a cytokine shown 
to promote Th17 differentiation and thereby IL-17 secretion (Colucci et al., 2005).  
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  The profile of cytokines secreted by B cells from PD patients is similar to the 
pro-inflammatory cytokine profile of B cells from individuals with T2D (Nikolajczyk et 
al., 2012). Jagannathan et al. (2010) showed that B cells from T2D patients secrete a 
relatively high concentration of IL-8 while unable to produce significant amounts of anti-
inflammatory IL-10. Parallel work similarly showed that B cells from people with PD 
also produce high amounts of IL-8, although IL-10 was relatively highly produced as 
well (Jagannathan et al., 2009). Using RT-PCR, Zhu et al. (2014) found that P. gingivalis 
inoculated obese WT mice had increased local and systemic TNF-α and RANKL 
expression compared to obese B cell-null mice. This data indicates that obesity and oral 
dysbiosis may synergize atop the similarities in cytokine production in hosts with either 
disease alone. These data furthermore show that B cells are required for expression of 
osteoclastogenic cytokines in obese hosts and justify further examining the role of B cells 
in obesity/T2D associated PD.  
 
The role of T cells in PD and T2D 
 There is substantial evidence for roles of T cells in PD. Many studies of induced 
PD, especially in rodents, suggest that adaptive T cell immunity is required for alveolar 
bone destruction, since deletion of T cells results in resistance to the disease (Cheng et 
al., 2014; Baker et al., 1999, 2001, 2000; Jiao et al., 2013). T cells are divided into two 
subsets: CD4+ T helper cells and CD8+ T cytotoxic cells. CD4+ T helper cells respond to 
antigen presentation by a combination of antigenic peptide plus MHC class II molecules 
that are expressed by APCs. CD8+ T cytotoxic cells similarly respond to antigen 
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presentation by MHC class I molecules on APCs (Taubman and Kawai, 2001). CD8+ 
cytotoxic T cells are important for immune defense against intracellular pathogens, 
including viruses and bacteria. When activated, CD8+ T cells kill infected cells through 
various mechanisms, including pro-inflammatory cytokines. The role of CD8+ T cells in 
PD, however, remains unclear. While these cells do produce cytokines necessary to illicit 
the proper immune defense against a PD pathogen, it is also thought that CD8+ T cells 
participate in lysis of bacteria-infected or bacteria-damaged tissues and cells (Teng, 2003; 
Gemmell et al., 2007). While the CD4+/CD8+ ratio has been found to be diminished in 
PD lesions compared to healthy sites (Cole et al., 1987; Stoufi et al., 1987; Johannessen 
et al., 1990; Jully et al., 1986), other studies reported an increase in the CD4+/CD8+ ratio 
(Syrjanen et al., 1984; Modeer et al., 1990). Further work is needed to determine the role 
of CD8+ T cells in PD, including examining the CD4+/CD8+ ratio in stable vs. 
progressive PD lesions (Okui et al., 2014).  
 While both CD4+ and CD8+ cell subpopulations have been identified in PD 
lesions (Mathur and Michalowicz, 1997), a majority of PD research in regards to T cells 
has focused on the CD4+ T helper cells. The classical function of CD4+ T helper cells is 
to activate B cells to produce antigen specific antibodies, which is accomplished, in part, 
by CD4+ T helper cell cytokine production. In PD, lack of CD4+ T helper cells in mice 
resulted in less bone resorption in response to a P. gingivals challenge compared to CD8+ 
cytotoxic T cell deficient mice (Baker et al., 1999) indicating the prominent role of CD4+ 
T helper cells in PD. Furthermore, cytokine production by this cell subset regulates the 
inflammatory milieu in PD, and research since the 1990s has been conducted to 
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characterize the cytokine profile in order to identify the specific key players responsible 
for the chronic inflammatory state in PD. 
CD4+ T helper cells differentiate into Th1, Th2, Th17 and Treg cells, each with a 
characteristic profile of secreted cytokines. Inflammation in PD was initially thought to 
be mediated solely by Th1 and Th2 cells with Th1 cells secreting IL-2 and IFN-y and 
Th2 cells secreting IL-4, IL-5, IL-6, IL-10, IL-13 and IL-25 (Zhu and Paul, 2008; 
Berglundh, and Donati, 2005). However, there is controversy regarding which cell type 
dominates in PD due to many factors, including lack of methods used to quantify 
cytokine production, different cytokine profiles found in natural vs. artificial PD 
induction, and use of cells from different sources (gingival cells vs. peripheral blood 
mononuclear cells) (Gemmell and Seymour, 2000). By a quick search, one can easily 
recognize the discrepancies in the literature as evidenced by seemingly contradictory 
study results. Since the majority of cells in PD lesions are B cells, it is assumed by many 
that Th2 cells and related cytokines dominate in PD given that one function of Th2 cells 
is to activate B cells (Berglundh and Donati, 2005; Lappin et al., 2001; Fokkema et al., 
2002). The finding that Th2 cells dominate in PD lesions over Th1 cells was corroborated 
by Tokoro et al. (1997) who found that Th2 associated cytokines were higher in PD 
gingival cells than controls using in situ hybridization techniques. Furthermore, Th1 
associated IL-2 was low in PD and gingivitis cells thus leading the researchers to 
conclude that Th2 cells dominated over Th1 cells in PD lesions. However, dominance of 
Th1-related IL-2 and IFN-y in PD lesions over Th2 cytokines in PD has also been 
suggested (Takeichi et al., 2000; and Bickel et al., 2001). There is also evidence that Th1 
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and Th2 cells contribute equally to the inflammatory response in PD (Berglundh and 
Donati, 2005). Berglundh et al. (2002a,b) used immunohistochemical double staining 
technique to identify Th1 and Th2 related cytokine production from gingival cells from 
biopsies of individuals with PD. Using stereologic quantification, no difference was 
found in the proportion of cells representing either Th category.  
There are limitations, however, to the Th1 and Th2 paradigm to explain the 
pathogenesis of PD (Cheng et al., 2014). In 2003, it was found that Th17 cells are derived 
from naïve CD4+ T cells and are characterized by an IL-17, IL-21, and IL-22 cytokine 
profile (Zhu et al., 2010). IL-17 and IL-21 are cytokines that are not expressed by Th1 or 
Th2 cells and have been found to be expressed in PD lesions, thus leading researchers to 
conclude that the Th17 cell subset must be involved in the pathogenesis of PD (Cheng et 
al., 2014; Gaffen and Hajishengallis, 2008; Dutzan et al., 2012; Moutsopoulos et al., 
2012). The involvement of Th17 cells in the pathogenesis of PD was corroborated by 
researchers who found that the levels of IL-17 are greater in gingival tissues from PD 
patients compared to healthy controls using immunohistochemistry and flow cytometry 
(Beklen et al., 2007; Cardoso et al., 2009; Konermann et al., 2011, Adibrad et al., 2012). 
It is unclear, however, as to whether Th17 cells play a destructive or protective role in the 
pathogenesis of PD. IL-17 receptor deficient mice display a defective or significant delay 
of neutrophil recruitment to sites of bacterial invasion (Kelly et al., 2005). When these 
mice are exposed to pathogenic PD bacteria, such as P. gingivalis, they develop increased 
alveolar bone destruction (Yu et al., 2007). As a result, IL-17 recruitment of neutrophils 
to inflamed gingiva may protect from the invasion of pathogenic bacteria and may be a 
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critical step in host defense (Cheng et al., 2014). IL-17, however, is also an 
osteoclastogenic cytokine (Zhu and Nikolajczyk, 2014), and IL-17 induced RANKL 
expression on osteoblasts in rheumatoid arthritis (a chronic inflammatory disease with a 
similar pathogenesis as PD) contributes to bone destruction (Sato et al., 2006). Further 
research is needed to determine if there is direct evidence that IL-17 induces RANKL 
expression in PD tissue (Cheng et al., 2014). 
It is also unsurprising that like PD, obesity is characterized by a shift to a pro-
inflammatory T cell milieu (Zhu and Nikolajczyk, 2014). As adipose tissue expands, 
infiltrating CD8+ and CD4+ T cells secrete pro-inflammatory cytokines, such as IFN-γ, 
and contribute to the overall pro-inflammatory cytokine profile of obesity-associated T2D 
(Ip et al., 2015). The CD8+ T cell response, however, may be self-limiting due to impact 
of an effector molecule (Ip et al., 2015) indicating that CD4+ T cells may play the major 
role in obesity-associated T2D inflammation. Specifically, obesity associated 
inflammation is characterized by a dominance of pro-inflammatory Th1/Th17 T cells and 
a decrease in anti-inflammatory Tregs (Feuerer et al., 2009). It is hypothesized that 
obesity and/or obesity-associated T2D potentiates PD by priming the immune system, 
and it is noteworthy that similar alterations in adaptive host response in obesity and/or 
obesity associated T2D mirrors that of PD as described above. This justifies 
hypothesizing that Th1/Th17 T cells may be the driving force behind the two-way 
relationship between the two diseases. While evidence for altered T cell function of 
diabetics with PD is limited, preliminary evidence by Santos et al. (2010) and Ribeiro et 
al. (2011) provide evidence that the pattern of cytokines from GCF of PD patients with 
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T2D might be related to glycemic status and indicate a trend towards domination of 
Th1/Th17 related cytokines in T2D-associated PD. !
 
Objectives 
 The objectives of this study are as follows: to characterize the inflammation 
present in gingival tissue immune cells in subjects with periodontitis (PD) and subjects 
with type II diabetes mellitus and periodontitis (T2D/PD) compared with healthy subjects 
(H); to identify the effect of T2D on inflammation in PD; and to determine the 
predominant cell type responsible for the production of pro-inflammatory cytokines. 
Previous studies examined inflammation in PD using methods that allow for only the 
estimation and not quantification of the level of immune reactivity, such as q-PCR, 
immunofluorescence, and immunohistochemistry. Our study accurately quantifies 
function based on cytokine production by use of the Enzyme Linked ImmunoSpot 
(ELISPOT) assay. ELISPOT is a sensitive immunoassay that allows for the quantification 
of the number of cytokine producing cells on a single cell level without being skewed by 
receptor binding or protein degradation. Furthermore, our study utilizes PD gingival 
immune cells from human subjects with natural infection, which allows us to get a 
snapshot of immunopathogenesis of disease during its natural course. This is in contrast 
to previous studies which used animal models to examine the effect of T2D on PD and 
relied on artificial induction of PD by the use of pathogenic bacteria. Our data will bring 
researchers and clinicians one step further to identifying therapeutic targets for PD with 
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the ultimate goal of prevention or more effective treatment of this global disease.  
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METHODS 
 
Sample collection  
 Study participants were recruited from Henry M. Goldman School of Dental 
Medicine Department of Periodontology at Boston University. Participants were not 
compensated and gave informed consent to collect their gingiva samples removed during 
standard of care treatment. The exclusion criteria included smoking, antibiotic use, 
steroid use, drug abuse, alcohol abuse, autoimmune disease, cancer within the past 5 
years, seasonal allergy medications, and any underlying oral health conditions other than 
PD. Healthy (H) gingival samples (n=4) were obtained from subjects without PD from 
crown lengthening procedures. PD gingival samples (n=19) and type II diabetes mellitus 
with periodontitis (T2D/PD) gingival samples (n=3) were obtained as lesions that did not 
resolve following routine SRP for treatment of PD. Recruitment of T2D/PD subjects was 
determined by previously diagnosis of T2D from patients’ medical records. Diagnosis of 
PD was made during routine dental exams at Henry M. Goldman School of Dental 
Medicine.  
 
ELIPSPOT assay: Primary antibody coating 
 The enzyme-linked immunospot assay (ELISPOT) (Milipore, #MAHA or MAIP)  
 plate was first coated with the primary (capture) antibody under a sterile hood in the 
morning before receiving the gingival tissue sample. First, 500µl of sterile phosphate 
buffered saline (PBS) was added to Eppendorf tubes assigned for a panel of eleven 
different cytokines (IL-2, IL-4, IL-6, IL-8, IL-10, IL-13, IL-17a, TNF-α, IFN-γ, MIP3, 
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and Granzyme B). The appropriate amount of each primary antibody was then added to 
the corresponding Eppendorf tube according to the antibody titration concentration (table 
1). The Eppendorf tubes were flicked to mix and then transferred to a labeled 12 column 
reservoir. The ELISPOT plate rows were labeled as row 1: null (no cells), row 2: CD4+, 
row 3: CD8+, row 4: CD11b+, row 5: CD19+, and row 6: CD45+. The ELISPOT plate 
columns were labeled as column 1: null (no antibody), column 2: IL-2, column 3: IL-4, 
column 4: IL-6, column 5: IL-8, column 6: IL-10, column 7: IL-13, column 8: IL-17a, 
column 9: TNF-α, column 10: IFN-γ, column 11: MIP3, and column 12: Granzyme B. 
Using a multichannel pipette, 50µl of each antibody was added to the appropriately 
labeled wells. The plate was gently tapped to fully cover each well and air bubbles were 
popped using a sterile pipette tip. The plate was wrapped in damp paper towels, sealed in 
a plastic bag, and left in a drawer in a 4°C cold room for approximately 3 hours.  
 
Processing of gingiva samples 
 The gingival tissue sample collected at Henry M. Goldman School of Dental 
Medicine was placed in a 15mL conical tube with RPMI complete medium (Gibco Life 
Technologies, Gaithersburg, MD) supplemented with 10% fetal bovine serum (Atlanta 
Biological, Norcross, GA) and 1% Penicillin-Streptomycin (Sigma Aldrich, St. Louis, 
MO). The sample was placed on ice in a Styrofoam container and was transported 
quickly to the Boston University School of Medicine Department of Microbiology for 
same day processing. The gingiva tissue sample was placed in a petri dish in a sterile 
hood and rinsed with PBS. Sterile tweezers were used to remove all blood clots from the 
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gingival tissue. Once all blood clots were removed, the gingival tissue sample was placed 
in a clean petri dish. 1-2mL of Worthington collagenase I (LS004196), 1 mg/ml, in 
Medium 199 supplemented with 1% BSA (Gibco, Gaithersburg, MD) was added to the 
tissue sample. The tissue was then cut into very small fragments using two sterile razor 
blades inside the petri dish in order to digest the tissue. Once fragmented as much as 
possible, the gingival tissue pieces were transferred to a new 15mL conical tube using a 
2mL glass pipette with the end snapped off in order to prevent any fragments from 
getting stuck in the glass pipette. All of the fragments were removed with care from the 
petri dish and glass pipette. 10-12mL of additional collagenase was added to the 15mL 
conical tube. The conical tube containing the gingival fragments was then placed in a 
shaker set at 220 rpm at 37°C for one hour in order to complete the tissue digestion.  
 While the tissue was being digested, an aliquot of peripheral blood mononuclear 
cells (PBMCs) were thawed and prepared in order to serve as a positive control for the 
ELISPOT. The PBMCs were thawed in RPMI, washed with FACS buffer, and stored at 
4○ C until the gingival fragments were digested and prepared. After digestion of the 
gingival fragments, all liquid and fragments were filtered through a 70 micron BD filter 
into a clean petri dish. Next, 2-3mL of FACS buffer was added to the 15mL conical tube 
in order to remove all remaining fragments. The plunger from a 3mL syringe was used to 
mash the remaining tissue fragments in the 70 micron BD filter in order to remove any 
additional cells from the tissue. Per above, 3-5mL of FACS buffer was used to wash out 
the filter in order to collect all gingival cells. The wash-through liquid was transferred 
into a new 15 mL conical tube and additional FACS buffer was added until the volume of 
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liquid reached 15mL.  
 Next, the gingival cells were centrifuged (1200 rpm, 10 min, break on) and the 
PBMCs were centrifuged at 2200 RPM for 6 minutes. After centrifugation, the 
supernatant was removed from both the gingival cells and PBMCS. The gingival cells 
were then resuspended in 15mL of PBS (1200 rpm, 10 min, break on) and the PBMCs 
were resuspended in 1mL FACS buffer.  
 After the centrifugation, the supernatant was aspirated from each cell sample. 
50µl of 1:200 diluted Zombie Aqua stain solution to differentiate live vs. dead cells 
(Biolegend, Dedham, MA) was added to the gingival cells, mixed by pipetting,  and 
transferred to an Eppendorf tube. 5µl of Zombie Aqua stain (undiluted) was added to the 
PBMC sample and mixed by pipetting. Both Eppendorf tubes were stored on ice for 30 
minutes in the dark.  
  A master mix of staining solution to label various immune cell surface markers 
was prepared by adding 100µl of FACS buffer to an Eppendorf tube and appropriate 
amounts of each antibodies listed in table 2. The master mix was then stored in ice until 
needed.  
 After completion of PBMC and gingival cell preparation, 1.2mL of PBS was 
added to both the tubes. The Eppendorf tubes were centrifuged (2200 rpm, 6 minutes) 
and supernatant aspirated. 50µl of the master mix the staining solution was added to both 
samples, pipetted to mix, and incubated on ice in the dark for 30 minutes. After this, 1mL 
of of FACS buffer was added to each Eppendorf tube, pipetted to mix, and centrifuged 
(2200 rpm, 6 minutes). The supernatant was aspirated from each tube, and the pellet was 
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resuspended in 300µl of FACS buffer and left on ice in the dark until sorting.  
 
Cell sorting and plating 
 The Eppendorf tubes containing the gingival cells or PBMCs were transferred on 
ice to the Boston University Flow Cytometry Core Facility. The gingival cells were 
sorted using the BD FACSARIA II SORP. The cells were gated according to CD45+ 
expression and subpopulations were gated and sorted according to CD4+, CD8+, CD11b+, 
and CD19+ cell surface expression. The PBMCs were gated and sorted according to only 
CD45+ cell surface expression and served as a positive control for the ELISPOT plate. 
The 5 cell fractions were sorted into FACS sorter collection tubes containing 200µl of 
RPMI complete media. The cell count for each cell fraction was recorded. CD4+, CD8+, 
CD19+, and CD45+ cells were stimulated by adding 9µl PMA and 45µl ionomycin 
diluted in PBS. CD11b+ cells were stimulated by adding 18µl of LPS. The cells were 
plated in a volume of 150µl of RPMI medium with the appropriate stimuli and incubated 
for approximately 15-20 hours at 37°C.  
 
ELIPSPOT assay: Secondary antibody coating 
 After incubation, the contents of the ELISPOT plate were removed and any 
remaining liquid was washed with 200µl of PBS. The plate was then washed twice with 
200µl of PBST (PBS 1x + tween 20: a detergent that decreases non-specific adherence). 
The solutions of biotinylated (secondary or detection) antibodies were prepared by 
adding 500µl of PBSTB (PBS 1x, tween, 2% bovine serum albumin) to Eppendorf tubes 
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and then adding the appropriate amount of biotinylated antibodies to the corresponding 
labeled Eppendorf tube (table 1). 50µl of biotinylated antibodies was added to the 
appropriate wells. The ELISPOT plate was then wrapped in damp paper towels, sealed in 
a plastic bag, and incubated in the dark in a 4°C cold room for approximately 24 hours. 
 
ELISPOT assay: Development of plate 
 After the 24 hours, the ELISPOT plate was washed three times with 200µl of 
PBST. 50µl of a Streptavidin conjugated alkaline phosphatase dilution (AP-Conjugated 
Streptavidin, Jackson Immunoresearch, West Grove, PA 016-050-084) (1:1000, 
streptavidin in PBSTB) was added to each well using a multichannel pipette and 
incubated at room temperature for 30-45 minutes and then washed with 200µl of PBSTB. 
The plastic backing of the ELIPSPOT plate was then removed so that the membrane of 
the ELSIPOT plate wells were exposed on both sides. The plate then soaked fully 
submerged in PBST for one hour at room temperature. During this time, the staining 
solution to develop the wells was made in a 15mL conical tube containing Vector Blue 
substrate mix (AP Substrate Kit III, #SK-5300, Vector Labs Burlingame, CA) and 5mL 
of 100mM Tris HCL) and wrapped in aluminum foil to keep out light. Steptavidin is a 
protein isolated from the bacterium Streptomyces avidinii and can be used to detect biotin 
in a signal amplification scheme in conjunction with chromogenic substrates or 
fluorogenic substrates. After one hour, the plate was removed from the PBST soaking 
solution. The remaining liquid was removed by gentle tapping and the plate was rinsed 
with PBS to remove any remaining detergent from the wells. With minimal exposure to 
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light, the plate was propped up so that the membrane was not in contact with any 
surfaces. 100µl of the staining solution was added to each well using a multichannel 
pipette and left in the dark for 15 minutes. The plate was then washed with distilled water 
to remove the staining solution and to expose any developed spots on the well 
membranes. The plate was then left to dry for 24 hours and periodically checked for any 
spots on the well membranes. The next day, the plate was placed under a microscope to 
count the number of spots on each well to calculate the percentage of cytokine producing 
cells (spots) per number of plated cells per well.  
 
Antibody)
Primary)
antibody)final)
concentration)
Primary)
antibody)(µl))
(added)to)500µl)
PBS))
Secondary)
antibody)final)
concentration)
Secondary)
antibody)(µl))
(added)to)500µl)
PBSTB))IL=2! 1:60! 8.5! 1:60! 8.5!IL=4! 15µg/mL! 7.5! 1µg/mL! 0.5!IL=6! 15µg/mL! 7.5! 1µg/mL! 0.5!IL=8! 1:60! 8.5! 1:60! 8.5!IL=10! 1:60! 8.5! 1:60! 8.5!IL=13! 1:60! 8.5! 1:60! 8.5!IL=17a! 5µg/mL! 10.0! 4µg/mL! 2.0!IFN=γ! 15µg/mL! 7.5! 1µg/mL! 0.5!TNF=α! 1:60! 8.5! 1:60! 8.5!Granzyme!B! 1:60! 8.5! 1:60! 8.5!MIP3! 5µg/mL! 10! 2µg/mL! 1!
 
  
 
Table 1: Primary and secondary antibody titration concentrations for ELISPOT 
 plate added to either 500µl of PBS or PBSTB !
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Master)mix)staining)
solution) Ratio)
Amount)added)to)
100µl)FACS)buffer)
(µl))CD19!BUV395! 1:100! 1.0!CD45!PacB! 1:200! 0.5!CD20!FITC! 1:200! 0.5!CD16!PE! 1:200! 0.5!CD8!PerCP/Cy5.5! 1:400! 0.25!CD11b!PE/Cy7! 1:200! 0.5!CD4!APC! 1:200! 0.5!CD56!AF700! 1:100! 1.0!CD3!APC/Cy7! 1:200! 0.5!
 
 
Statistical analysis  
Statistical significance for percentage of cells producing cytokines was calculated 
by one-way ANOVA among the three groups using Bonferroni correction. 
  
Table 2: Flow cytometry antibody concentrations and volume added to 100µl 
FACS buffer !
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RESULTS !
Patient characteristics ! ! Total! H! PD! T2D/PD!
Patients)included! 26! 4! 19! 3!
Mean)probing)depth)(mm))
(mean)±)SD)! ! 2.75!±!0.05! 6.6!±!2.6! 8.6!±!3.2!
Males! 8! 1! 5! 2!
Females! 18! 3! 14! 1!
BMI) ! 25!±!4! 25!±!4! 25!±!1!
Age)(years))(mean)±)SD)) ! 47!±!13! 31!±!1.5! 49!±!1.5!
!
Three patient cohorts were recruited from Boston University Henry M. Goldman 
School of Dental Medicine Department of Periodontology: healthy (H) (n=4), 
periodontitis (PD) (n=19), and type II diabetes mellitus with periodontitis (T2D/PD) 
(n=3; Table 3). The H cohort served as the comparator for PD, and both the H and PD 
cohorts served as comparators for T2D/PD subject outcomes.  
Gingival samples from the H group were taken from crown lengthening 
procedures (CLP). CLP is a surgical procedure that is used to increase the exposure of the 
natural tooth. Gingival samples from the PD and T2D/PD cohorts were taken from 
routine SRP. SRP is a conventional and non-surgical procedure used to treat PD.  
All gingival samples were collected following informed consent of the patients 
and patient characteristics were recorded (table 3). Patients were not compensated for 
time spent on research since the gingival samples were byproducts of CLP and SRP and 
are typically discarded as waste. Mean probing depth (distance from gingival margin to 
Table 3: Patient characteristics of H, PD, and T2D/PD cohorts 
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the base of the gingival crevice) was recorded as part of routine dental examinations with 
a periodontal probe prior to gingival treatment in order to diagnose chronic PD according 
to Armitage 1999 criteria (table 3). Mean probing depth of healthy gingiva is 1 to 3mm, 
and probing depths greater than 3mm is associated with PD.  
 
)
Statistical analysis: CD45+ cell subgroup frequencies 
Statistical analysis began with determining the cell frequency of CD45+ 
subgroups present in the three cohorts: CD4+, CD8+, CD11b+, CD19+, and CD56+ cells. 
This analysis would indicate which cell subgroup was predominant in each cohort of 
gingival samples. CD45 is a receptor linked protein tyrosine phosphatase that is present 
in all cells of hematopoietic lineage. The presence of this marker was the first step of the 
gating strategy to identify B cells and T cells in the gingival cell samples. Cells were then 
further gated according to their respective CD marker, which are specific to different 
immune cell subsets. Cell frequencies were expressed as percent total of CD45+ cells for 
each gingival cell (figure 1). CD4+ cells were the predominant cell type across all three 
groups (25.9-30.8, SE ± 1.81-4.21) followed by CD8+ (19.8-22.1, SE ± 1.28-5.82), 
CD11b+ (10.4-11.7, SE ± 1.47-4.59), CD19+ (4.0-7.5, SE ± 0.69-3.41), and CD56+ (1.7-
2.6, SE ± 0.11-0.66) cells. 
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Statistical analysis: CD4+ T helper cells cytokine secretion 
 Overall, CD4+ T helper cells from H gingival cells exhibited the lowest level of 
overall cytokine secretion compared to PD and T2D/PD gingival cells (table 4). The 
mean IL-2, IL-4, IL-6, IL-8, IL-13, IL-17, Granzyme B, and Mip3 production for CD4+ T 
helper cells was found to be not statistically significant (p>0.05). However, there was a 
trend of highest IL-17 and Mip3 cytokine production in T2D/PD compared to H and PD 
(table 4). T2D/PD IL-10 production was found to be statistically significant compared to 
H (p=0.0002) and PD (p<0.0001) (figure 2). T2D/PD TNF-α cytokine production was 
found to also be statistically significant compared to H (p=0.0003) and PD (p=0.004) 
(figure 2). Lastly, T2D/PD IFN-γ production was statistically significant compared to PD 
(p=0.0307 (figure 2). 
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)
H)
(percent)positive)
cells))
(mean)±)SE)!
PD)
(percent)positive)
cells))
(mean)±)SE)!
T2D/PD)
(percent)positive)
cells))
(mean)±)SE)!
ILP2) 1.33!±!0.98! 3.59!±!0.93! 8.64!±!3.05!
ILP4) 0.32!±!0.17! 0.22!±!0.090! 0.13!±!0.081!
ILP6) 0.12!±!0.12! 0.01!±!0.010! 0.04!±!0.037!
ILP8) 0! 0.25!±!0.05! 0.42!±!0.21!
ILP10) 0.37!±!0.37! 0.17!±!0.059! 1.26!±!0.29!
ILP13) 0! 0.10!±!0.060! 0.05!±!0.47!
ILP17) 1.01!±!0.26! 1.26!±!0.27! 1.28!±!0.27!
TNFPα) 1.89!±!1.34! 2.75!±!0.24! 7.04!±!1.59!
IFNPγ) 4.46!±!2.01! 4.15!±!0.75! 10.16!±!3.49!
Granzyme)B) 0.08!±!0.080! 0.31!±!0.092! 0.43!±!0.30!
Mip)3) 1.41!±!0.80! 1.85!±!0.61! 3.67!±!0.43!
 
 
 
 
 
 
 
 
 
 
 
 
Table 4: Mean (± SE ) values of CD4+ cytokine producing cells for H (n=4), PD 
(n=19), and T2D/PD (n=3) !
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Figure 2: Shown are percentage (± SE) of CD4+ cytokine producing cells for IL-10, 
IL-17, IFN-γ, TNF-α, and Mip3 for H (n=4), PD (n=19), and T2D/PD (n=3) 
(*=T2D/PD compared to H; $=T2D/PD compared to PD) !
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Statistical analysis: CD8+ T cytotoxic cells  
CD8+ T cells from all cohorts expressed IL-2, TNF-α, and IFN-γ although 
frequency of cytokine expressing cells was similar amongst disease states and not 
statistically different (p>0.05) (table 5). T2D/PD production of Granzyme B was 
statistically significant compared to PD (p=0.0141) (figure 3). The ELISPOT wells 
showed that few to no cells produced IL-4, IL-6, IL-8, IL-17, and Mip3 (table 5). 
 
 !!!!!!
! H)(percent)positive)cells))
(mean)±)SE)!
PD)
(percent)
positive)cells))
(mean)±)SE)!
T2D/PD)
(percent)
positive)cells))
(mean)±)SE)!
ILP2! 5.80!±!1.67! 4.69!±!0.65! 7.77!±!1.54!
ILP4! 0! 0.34!±!0.15! 0.26!±!026!
ILP6! 0.18!±!0.18! 0.04!±!0.028! 0!
ILP8! 0.19!±!0.19! 0.02!±!0.019! 0.16!±!0.10!
ILP10! 0! 0.04!±!0.022! 0.12!±!0.061!
ILP13! 0! 0.02!±!0.023! 0.15!±!0.077!
ILP17! 0.56!±!0.56! 0.02!±!0.012! 0.42!±!0.042!
TNFPα! 5.33!±!2.94! 6.55!±!0.85! 9.51!±!1.25!
IFNPγ! 17.06!±!4.63! 13.06!±!1.22! 12.38!±!1.07!
Granzyme)B! 3.27!±!1.63! 2.52!±!0.39! 5.96!±!1.83!
Mip)3! 0.54!±!0.16! 0.10!±!0.045! 0.15!±!0.077!
Table 5: Mean (±)SE) values of CD8+ cytokine producing cells for H (n=4), 
PD (n=19), and T2D/PD (n=3) !
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Figure 3: Shown are percentage (± SE) of CD8+ cytokine producing cells for IL-2, 
TNF-α, IFN-γ, and Granzyme B in H (n=4), PD (n=19), and T2D/PD (n=3) 
(*=T2D/PD compared to H; $=T2D/PD compared to PD) !
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Statistical analysis: CD11b+ myeloid cells 
As indicated by table 6, IL-6, IL-8, and TNF-α production was observed across 
H, PD, and T2D/PD. However, no statistical difference amongst cohorts was observed. !!!!
 
 
 
 
 
 
 
Statistical analysis: CD19+ B cells and CD56+ natural killer cells  
Cytokine production of IL-6 by CD19+ B cells was similar across all cohorts 
(p>0.05) (table 7). T2D/PD production of IL-8 was found to be significantly higher 
compared to PD (p=0.0373) (figure 4). There was little to no production of IL-2, IL-4, 
IL-10, IL-13, IL-17, TNF-α, IFN-γ, Granzyme B, and Mip3 across all cohorts (table 7). 
Furthermore, the number of CD56+ natural killer cells was too low to be collected by cell 
sorting. Therefore, no data were available for CD56+ cells.  !
! H)(percent)positive)cells))
(mean)±)SE))
PD)
(percent)
positive)cells))
(mean)±)SE))
T2D/PD)
(percent)
positive)cells))
(mean)±)SE))
ILP2! 0! 0! 0!
ILP4! 1.67!±!0! 0! 0!
ILP6! 4.23!±!3.54! 1.45!±!0.79! 2.17!±!1.13!
ILP8! 12.60!±!7.60! 6.68!±!1.65! 4.25!±!1.68!
ILP10! 0! 0.08!±!0! 0.61!±!0.33!
ILP13! 0! 0! 0!
ILP17! 0! 0! 0.16!±!0.15!
TNFPα! 12.78!±!0! 2.08!±!0.70! 0.86!±!0.72!
IFNPγ! 0! 0.57!±!0.87! 0!
Granzyme)B! 0! 0.61!±!0.22! 1.33!±!1.33!
Mip)3! 0! 0.53!±!0! 0.82!±!0.13!
Table 6: Mean (±)SE) values of CD11b+ cytokine producing cells for H (n=4), 
PD (n=19), and T2D/PD (n=3) 
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! H)(percent)positive)cells))
(mean)±)SE)!
PD)
(percent)
positive)cells))
(mean)±)SE)!
T2D/PD)
(percent)
positive)cells))
(mean)±)SE)!
ILP2! 0! 0! 0.18!±!0!
ILP4! 0.36!±!0! 0.21!±!0.17! 0!
ILP6! 0.36!±!0! 1.65!±!0.53! 2.50!±!2.50!
ILP8! 1.40!±!1.40! 0.88!±!0.25! 4.00!±!0.07!
ILP10! 0! 0.22!±!0.17! 0.18!±!0!
ILP13! 0! 0.05!±!0.05! 0.18!±!0!
ILP17! 0! 0.30!±!0.23! 0.18!±!0!
TNFPα! 0! 0.75!±!0.32! 1.12!±!0!
IFNPγ! 0! 0.09!±!0.089! 0!
Granzyme)B! 0! 0! 0.18!±!0!
Mip)3! 0! 0! 0!
Table 7: Mean (±)SE) values of CD19+ cytokine producing cells for  
H (n=4), PD (n=19), and T2D/PD (n=3) 
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Figure 4: Shown are percentage (± SE) of CD19+ cytokine producing 
cells for IL-6 and TNF-α in H (n=4), PD (n=19), and T2D/PD (n=3) 
(*=T2D/PD compared to H; $=T2D/PD compared to PD) 
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DISCUSSION 
 ! As the prevalence of obesity and T2D increases worldwide, clinicians and oral 
health professionals will be faced with an increasing number of patients with PD. PD has 
significant impacts on an individual’s quality of life, including functional limitation, 
psychological discomfort, physical discomfort, and psychological disability (Ferreira et 
al., 2017). As a result, it is imperative to examine the immunopathogenesis of the disease 
to develop therapeutic targets for the treatment, management, and prevention of PD. 
While epidemiological studies have established the association between PD and T2D, 
previous experimental data have failed to conclusively identify the immunological 
connection between PD and T2D in part due to the implementation of relatively limited 
study methods, such q-PCR, immunofluorescence, and immunohistochemistry 
techniques. These methods only allow for the estimation, not quantification, of immune 
cell function and may be responsible for the discrepancies in results and interpretation in 
the PD/T2D literature. With the use of flow cytometry analysis and sorting and the 
Enzyme Linked ImmunoSpot (ELISPOT) assay, a sensitive immunoassay that allows for 
the quantification of the number and frequency of cytokine producing cells, we were able 
to accurately quantify cytokine producing cells from the gingiva of H, PD, and T2D/PD 
subjects to identify the effect of T2D on immune cell-generated inflammation in PD.  
 We identified CD4+ T helper cells as the predominant immune cell type in 
gingival tissues from H, PD, and T2D/PD subjects, followed by CD8+ cytotoxic T cells 
across all groups. Furthermore, upon stimulation, the highest frequency of gingival CD4+ 
T helper cells that produced IL-2, IL-10, IFN-γ, and TNF-α came from subjects with 
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T2D-potentiated PD. This group of cytokines indicate that pro-inflammatory Th1 cells 
are the predominant cell subtype present in T2D/PD gingival cells but not in gingival 
cells from the other two cohorts. This finding, therefore, suggests that T2D increases 
inflammation in PD by an increase in Th1 cell persistence.  
 Our findings that T cells (CD4+ and CD8+ T cells) dominate in the healthy and 
disease states were recently corroborated by Duztan et al. (2016) who also found that T 
cells were the predominant cell type found in gingival biopsies from H and PD subjects 
using flow cytometry. However, the finding that T cells dominate in PD lesions is in 
contrast to much of the previously published research which indicates that B cells 
dominate in PD lesions (>65% of cell population in PD lesions) (Berglundh et al., 2007; 
Nikolajczyk, 2010). This could be attributed to the fact that patients recruited from our 
study had already received SRP for the treatment of PD. SRP removes plaque and tartar 
from the root surface and, therefore, reduces inflammation of the gingival tissues. The 
effect of SRP could have reduced that bacterial challenge and affected the microbial 
biofilm to an extent of reducing the host immune response and reduced the B cell to T 
cell ratio. This phenomenon can be considered as a period of “transient gingivitis” where 
the inflammation is partially resolved by SRP. If the bacterial virulence is not fully 
resolved by the clinician, however, the inflammation will reoccur with signs of 
periodontal damage. This hypothesis is corroborated by Berglundh et al. (1999) and 
Kleinfelder et al. (2001) who found that B cell and T cell frequencies declined in PD after 
non-surgical treatment. Another possibility for the low frequency of B cell collection by 
flow cytometry could have been due to the condition or status of the gingival tissue 
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biopsy upon receipt from the clinic (active vs. progressive lesion) or the inability of the 
collagenase to extract B cells from the gingival tissue. Experimental techniques could be 
improved in order to accurately determine cell populations in PD lesions in future studies. 
 Our finding that CD4+ T helper cells is the predominant T cell subpopulation 
present in gingival tissues is consistent with much of the previously published literature 
agreeing that CD4+ T cells dominate in PD lesions. However, the relative distribution of 
Th1, Th2, and Th17 cells in progressive PD lesions is a matter of much controversy in the 
literature. Our findings that Th1 cells dominate in PD lesions is supported by findings of 
Houri-Haddad et al. (2007) who showed that repeated challenges by P. gingivalis on 
mice gingival immune cells augmented the pro-inflammatory cytokines TNF-α and IFN-
γ while inhibiting the accumulation of the anti-inflammatory cytokine IL-10. 
Furthermore, Ebersole and Taubman (2000) concluded that gingival immune cells from 
PD lesions were positive for IL-2 and IFN-y but negative for IL-4 and IL-5, indicating a 
predominance of Th1 cells in PD lesions. However, this study consisted of only 6 study 
participants, raising concerns over statistical power of the analyses similar to those raised 
in our studies.  
Interestingly, our finding that Th1 cells dominate in progressive PD lesions is in 
contrast to some previously published research. There is a general consensus in the 
literature that Th2 cells dominate in progressive PD lesions and Th1 cells dominate in 
stable PD lesions. Using in situ hybridization, Tokoro et al. (1997) found that the mRNA 
densities of Th2-associated cytokines, IL-4 and IL-5, were increased in gingival immune 
cells of subjects with PD compared with patients with gingivitis, indicating the 
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predominance of Th2 cells in PD lesions. Furthermore, Yamamoto et al. (1997) isolated 
CD4+ T helper cells from PD lesions, used RT-PCR to identify mRNA cytokine 
production, and found a higher production of Th2-related cytokines than Th1-related 
cytokines. These study methods, however, are less than ideal because it is impossible to 
accurately quantify cytokine production using in situ hybridization and the level of 
mRNA expression does not necessarily correlate with level of protein expression. These 
conclusions that the Th1/Th2 ratio is low in PD due to a predominance of Th2 cells 
contradict our current understanding of immunology, as it is generally agreed that Th1 
cells are pro-inflammatory and Th2 cells are anti-inflammatory in nature, at least under 
some conditions. Other studies using mainly RT-PCR and immunohistochemistry 
methods to determine mRNA levels and cytokine production found no definitive pattern 
of Th1/Th2 expression in PD gingiva (Honda et al, 2006; Suarez et al., 2004; Fujihashi et 
al., 1996; Prabhu et al., 1996).  
In the last 15 years, the dominance of Th1/Th2 cell subsets in PD has been 
reinterpreted in light of the more recently described Th17 subset in gingival immune 
cells. Discovery of Th17 has forced researchers to reconsider findings that only examine 
the frequencies of Th1 and Th2 cells in PD lesions. Since gingival immune cells in our 
study were taken from progressive PD lesions, it is interesting that the frequency of IL-17 
cytokine production was not found to be statistical different amongst H, PD, and T2D/PD 
gingival immune cells since IL-17 is considered a driving force of inflammatory bone 
loss through its direct role in osteoclastogenesis and the upregulation of RANKL (Dutzan 
et al., 2016). This finding could be due to the fact that both types of subjects with PD 
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received SRP prior to gingival tissue excision, which could have diminished the 
inflammation in the PD lesion and affected the frequency of IL-17 producing cells. It 
would be interesting if further research could ethically analyze tissues prior to SRP to 
determine whether Th17 cells are more responsive to this treatment in PD which would 
trigger the question of whether IL-17 directly upregulates RANKL in PD as in other 
chronic inflammatory disorders, such as rheumatoid arthritis (Li et al., 2017).  
 A limitation to our study is that there were no gingival tissue samples from T2D 
without PD. It would have been interesting to investigate the inflammatory state of 
gingival immune cells of subjects with T2D without PD to determine if inflammation in 
these cells were equal, less than, or greater than H controls. Another limitation of this 
study was the low numbers of H and T2D/PD subjects recruited (n=4, n=3). The inability 
to recruit more subjects for these three cohorts was due to the patient population at 
Boston University Henry M. Goldman School of Dental Medicine and the stringent 
exclusion criteria by both the study and by the SOC guidelines at the Dental School. It 
would have also been interesting to obtain HbA1c levels of subjects recruited for the 
study as a measure of hyperglycemia. Instead, a diagnosis of T2D was indicated by the 
subjects’ medical history records. Measuring patients’ HbA1c levels would have allowed 
us to confirm a subject’s inclusion into a specific cohort as well as provide additional 
variables for analysis. However, much care was taken to match the BMI among the 
cohorts in order to prevent any confounding factors that may be promoted by obesity-
induced inflammation. Age was not matched among H, PD, and T2D/PD subjects which 
may have introduced error into the data interpretation. 
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Our data indicate that T2D increases inflammation in PD through an increase in 
Th1 cell function. In contrast to previous studies which did not use precise quantitative 
methods, our use of the ELISPOT assay allowed us to accurately determine that IFN-γ 
and TNF-α produced by CD4+ T cells might be responsible for driving inflammation in 
gingival tissues from PD associated with T2D, especially given the modest frequency of 
IL-10 (anti-inflammatory cytokine)-producing cells. Overall, modulating the above 
mentioned cytokines or specific immune cell generators of these cytokines might be a 
treatment strategy to combat PD associated with T2D, while remaining inappropriate for 
PD in metabolically healthy people.  
Most importantly, our data indicates that elevated IL-2 production was detected in 
both CD4+ and CD8+ T cells in PD and T2D/PD. IL-2 is important for many cellular 
functions, including Th1 and Th2 differentiation from naïve T cells and promoting 
cytotoxic CD8+ T cell activity. Furthermore, IL-2 stimulates the Th1 response in PD 
(Gemmell and Seymour, 1998; Gemmell et al., 2007). Therefore, IL-2 may be a 
therapeutic target for the detection and/or treatment of PD. This role of IL-2 in PD is of 
particular interest to our study since we determined Th1 cells to be the predominant cell 
type in PD lesions. Further research is needed, however, to specifically determine the 
effect of IL-2 down regulation on the progression of PD.  
  Overall, our data provides accurate and in-depth characterization of the immune 
cell network of PD associated T2D by identifying the dominant Th cell subset in PD 
lesions by the use of flow cytometry and the ELISPOT assay for the first time. By 
identifying Th1 cells as dominant in PD and T2D/PD, we provide evidence to support a 
!38 
direction of future research to prevent, alleviate, and treat T2D-potentiated PD: targeting 
of IL-2.  
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